About Cellectar Company Information

Cellectar is a clinical stage radiopharmaceutical company that designs and develops products to detect, treat and monitor a wide variety of human cancers.

Cellectar began independent lab activities in February 2003 after forming a company and raising initial funds in the 2000-2002 timeframe. Our product candidates combine phospholipid ethers analogs (PLEs), which are lipid-like molecules, with radioisotopes that destroy or image malignant cancer cells. Because only malignant tumor cells and tissues retain large amounts of these compounds, malignant cancer-selective retention of therapeutic or diagnostic doses of radioactivity can be achieved. To date, Cellectar has demonstrated specific uptake and retention of its product candidates in more than 45 tumor types tested in proof-of-principle preclinical animal studies. In addition, ten preclinical experiments have shown anti-tumor activity in each tumor type studied including breast, prostate, lung, glioma, pancreatic, melanoma, ovarian, uterine, renal and colorectal cancers. The compound, originally known as NM404, is being taken through the regulatory process as CLR1404.